GlassScriptPhysician profile
Lewis R Groden
NPI 1609896828
$6,372.05
in general payments reported to CMS, 2019-2025
21 companies · $960 in 2025
The $960 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,696 · 2020: $211 · 2021: $513 · 2022: $671 · 2023: $663 · 2024: $1,657 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,280.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $935.71 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $851.94 | 2023-2025 | Miebo, Xiidra |
| Alcon Vision LLC | $728.44 | 2019-2024 | |
| Glaukos Corporation | $431.90 | 2023-2024 | Istent Trabecular Micro-Bypass System Model Is3, Idose |
| Sight Sciences, INC. | $369.64 | 2019-2025 | Sion Surgical Instrument, Omni Surgical System |
| Harrow Eye, LLC | $321.43 | 2024 | Iheezo |
| Genentech USA, INC. | $308.09 | 2023-2024 | Vabysmo |
| Tarsus Pharmaceuticals, INC. | $276.91 | 2024-2025 | Xdemvy |
| Johnson & Johnson Surgical Vision, INC. | $271.24 | 2019-2022 | |
| Dompe US, INC. | $260.00 | 2019-2024 | Oxervate |
| Apellis Pharmaceuticals, INC. | $246.82 | 2022-2023 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $232.09 | 2019-2024 | Eylea Hd |
| Horizon Therapeutics Plc | $205.07 | 2021 | |
| Sun Pharmaceutical Industries INC. | $183.46 | 2019-2020 | |
| Amgen INC. | $150.00 | 2025 | Tepezza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $146.62 | 2025 | Acthar |
| Abbvie INC. | $123.26 | 2022 | |
| Ivantis, INC | $116.63 | 2019 | |
| Allergan, INC. | $115.91 | 2021 | |
| Shire North American Group INC | $53.80 | 2019 | |
| Novartis Pharmaceuticals Corporation | $43.09 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Groden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.